Reported diabetes or HbA1c ≥6.5% at blood collection 9 (5.7) 11 (4.5) 1 (0.7) 17 (4.9)
Diabetes reported after blood collection 3 (2.0) 8 (3.4) 5 (3.4) 6 (1.8) 0.14 0.14 0.09 0.11 * Odds ratio (95% confidence interval) from conditional logistic regression models conditioned on matching factors and adjusted for age at blood draw (years, continuous), fasting time (<4, 4-8, 8-12, ≥12 hours, missing) and race/ethnicity (White, Black, other, missing). P-value for trend calculated by entering the log-transformed metabolite as a continuous variable in logistic regression models † Odds ratios (95% CI) for the comparison of the fifth quintile to the first quintile (referent) for the circulating branched chain amino acids ‡ Sum of the concentrations of the three circulating branched chain amino acids, isoleucine, leucine and valine ± Cases were diagnosed with pancreatic cancer <2 years after blood collection and therefore these cases and their matched controls were not included in the primary analysis population ROC curves for risk prediction of pancreatic cancer. Base model includes: age at blood collection (continuous), cohort (HPFS, NHS, PHS, WHI; which also accounts for sex), race/ethnicity (white, black, other/missing), smoking status (never, past, current, missing) and fasting time (<4, 4-8, 8-12, ≥12 hours, missing) . Subsequent models also include the noted covariates.
Total BCAAs
Supplementary Figure 3 . Odds ratios for pancreatic cancer per standard deviation increase in branched chain amino acids stratified by covariates. Unconditional logistic regression to evaluate the association of circulating a, isoleucine, b, leucine, c, valine, and d, total branched chain amino acids with pancreatic cancer among participant subgroups. Regression models were adjusted for age at blood draw (years, continuous), fasting time (<4, 4-8, 8-12, ≥12 hours, missing) , race/ethnicity (White, Black, other, missing), cohort (HPFS, NHS, PHS, WHI, which also adjusts for sex), and smoking status (current, past, never, missing), excluding the stratification covariate. The solid squares and horizontal lines correspond to the multivariableadjusted OR (95% CI) per standard deviation increase in branched chain amino acid by subgroup. The area of the solid square reflects the groupspecific weight (inverse of the variance). The vertical line indicates an OR of 1.0. Abbreviations: BCAAs, branched chain amino acids; CI, confidence interval; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; OR, odds ratio; PHS, Physicians' Health Study; WHI, Women's Health Initiative.
Supplementary Figure 4 . Plasma BCAAs are elevated during subclinical disease in metabolically normal mice. a, Survival curve of KPC mice (n=9, median=146 days, range 54-339). b, Plot of total BCAAs in littermate control mice over the course of the study. c, Mean (±SEM) food intake per 24-hours in KP C and control mice (n=7 KP C, n=11 control mice). d, Mean (±SEM) plasma concentrations of branched chain amino acids for KP C and control mice (n=10 KP C, n=14 control mice). e, Ranked list of P-values from t-tests comparing circulating amino acids in KP C and control mice (n=10 KP C, n=14 control mice). f, Mean (±SEM) fasting blood glucose after overnight (16hr) fast (n=7 KP C, n=11 control). g, Mean (±SEM) AUC for KP C and control mice during intraperitoneal glucose tolerance test (n=7 KP C, n=11 control). h, Mean (±SEM) fasting blood glucose after daytime (6hr) fast (n=7 KP C, n=15 control). i, Mean (±SEM) inverse AUC for KP C and control mice during insulin tolerance test (n=7 KP C, n=15 control). Metabolite Mild chronic pancreatitis is neither a cause nor consequence of elevated plasma BCAAs. a, Mean (±SEM) total plasma BCAA levels over the experimental time course (n=8 caerulein, n=8 saline). b, Mean (±SEM) body weights (n=8 caerulein treated, n=8 saline treated). c, P-values for t-test comparing circulating amino acid levels in caerulein and saline treated mice after 10 weeks oftreatment, cys = cystine (n=8 caerulein treated, n=8 saline treated). The dashed red line indicates P-value of 0.05. d, Mean (±SEM) plasma concentrations of BCAAs for caerulein and saline treated mice after 10 weeks of treatment (n=8 caerulein treated, n=8 saline treated). e, H&E stain of pancreas from representative control mouse treated with saline for 10 weeks. f, H&E stain of pancreas from representative mouse treated with caerulein for 10 weeks. g, Trichrome stain of pancreas from representative control mouse treated with saline for 10 weeks. h, Trichrome stain of pancreas from representative mouse treated with caerulein for 10 weeks. i, Mean (±SEM) food intake per 24 hours. 2x BCAA diets contain twice the amount of BCAA found in normal mouse chow (1x BCAA) (n=7 1x BCAA, n=7 2x BCAA). j, Mean (±SEM) plasma concentrations of branched chain amino acids after 10 weeks of 1x and 2x BCAA diets (n=7 1x BCAA, n=8 2x BCAA, t-test, P=0.01 for Ile, P=0.03 for Leu, P=0.002). k, Mean (±SEM) body weights of mice after 10 weeks of each diet (n=7 1x BCAA, n=8 2x BCAA). l, Mean (±SEM) plasma amylase from mice fed the specified diets for 10 weeks (n=5 1x BCAA, n=5 2x BCAA). m, Mean (±SEM) plasma lipase from mice fed the specified diets for 10 weeks (n=5 1x BCAA, n=5 2x BCAA). n, H&E stain of pancreas from representative mouse treated with 1x BCAA diet for 10 weeks. o, H&E stain of pancreas from representative mouse treated with 2x BCAA diet for 10 weeks. No differences in short-term pool contributions to plasma BCAAs or incorporation of C-BCAAs into long-term pools. a, Mean (±SEM) food intake of C-BCAA labeled diet over a 2-hour period (n=8 KP C, n=6 control). b, Mean (±SEM) fully labeled plasma BCAA species normalized to food intake 2 hours after a pulse feed of C-BCAA labeled diet (n=8 KP C, n=6 control). c, Fractional labeling of the specified amino acids from a protein hydrolysate of pancreas and liver tissue obtained from overnight fasted KP C mice and control littermates (n=8 KP C, n=6 control). d, Fractional labeling of the specified plasma amino acids in KP C and control mice after overnight fast (n=8 KP C, n=6 control). 
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